In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 14 of 14

TitleConsultationTypeConsultation end date
Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]Review proposal consultationTechnology appraisal guidance
Heart failure - sacubitril valsartan [ID822]Review proposal consultationTechnology appraisal guidance
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]Review proposal consultationTechnology appraisal guidance
Tirzepatide for treating type 2 diabetes [ID3938]Review proposal consultationTechnology appraisal guidance
Empagliflozin in combination therapy for treating type 2 diabetesReview proposal consultationTechnology appraisal guidance
Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]Review proposal consultationTechnology appraisal guidance
Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962]Review proposal consultationTechnology appraisal guidance
Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) [ID756]Review proposal consultationTechnology appraisal guidance
Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]Review proposal consultationTechnology appraisal guidance
Canagliflozin in combination therapy for treating type 2 diabetesReview proposal consultationTechnology appraisal guidance
Dapagliflozin in combination therapy for treating type 2 diabetesReview proposal consultationTechnology appraisal guidance
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Draft guidanceTechnology appraisal guidance
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]Draft guidanceTechnology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All